Spyre Therapeutics (SYRE) Non-Current Assets (2015 - 2025)
Spyre Therapeutics' (SYRE) quarterly Non-Current Assets came in at $10000.0 in Q1 2025, down 96.96% YoY from $329000.0 in Q1 2024, and little changed on a QoQ basis from $10000.0 in Q4 2024.
Spyre Therapeutics (SYRE) Non-Current Assets (2015 - 2025) Analysis & Trends
Spyre Therapeutics (SYRE) has 11 years of Non-Current Assets data on file, last reported at $10000.0 in Q1 2025.
- Quarterly Non-Current Assets fell 96.96% year-over-year to $10000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $10000.0 (down 98.53% YoY) and the FY2024 annual result came in at $10000.0, down 96.98% from the prior year.
- Non-Current Assets was little changed at $10000.0 in Q1 2025, from $10000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $12.6 million in Q2 2021 to a low of $10000.0 in Q3 2024.
- A 5-year average of $5.9 million and a median of $8.1 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets climbed 16.03% — and 2024, when it slumped 99.24%.
- Tracing SYRE's Non-Current Assets over 5 years: stood at $11.0 million in 2021, then dropped by 19.47% to $8.9 million in 2022, then plunged by 96.28% to $331000.0 in 2023, then plunged by 96.98% to $10000.0 in 2024, then changed by 0.0% to $10000.0 in 2025.
- The last three Non-Current Assets figures came in at $10000.0 (Q1 2025), $10000.0 (Q4 2024), and $10000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 10,000.00 |
| Sep 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 331,000.00 |
| Mar 31, 2024 | 329,000.00 |
| Dec 31, 2023 | 331,000.00 |
| Sep 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 3.64 Mn |
| Mar 31, 2023 | 8.08 Mn |
| Dec 31, 2022 | 8.89 Mn |
| Sep 30, 2022 | 9.35 Mn |
| Jun 30, 2022 | 10.06 Mn |
| Mar 31, 2022 | 10.57 Mn |
| Dec 31, 2021 | 11.04 Mn |
| Sep 30, 2021 | 11.55 Mn |
| Jun 30, 2021 | 12.61 Mn |
| Mar 31, 2021 | 12.20 Mn |
| Dec 31, 2020 | 11.83 Mn |
| Sep 30, 2020 | 11.23 Mn |
| Jun 30, 2020 | 11.05 Mn |